5 results
This study has been transitioned to CTIS with ID 2023-507303-55-00 check the CTIS register for the current data. To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD with demonstrated…
This study has been transitioned to CTIS with ID 2023-510309-16-00 check the CTIS register for the current data. The primary objective to demonstrate that in CNOpatients with pain 3-monthly treatment with pamidronate will result in significant…
To prove in a randomized clinical trial in a translational setting that minocycline treatment (duration 3 months) can decrease markers of neuroinflammation and the gelatinase pathway in the cerebrospinal fluid (CSF) of patients with HCHWA-D (n=30)…
Primary: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in nrSPMSSecondary: 1. To evaluate safety, tolerability, and efficacy of SAR442168 compared to placebo on clinical endpoints, MRI lesions,…
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care